{"id":1767,"date":"2021-04-01T09:50:39","date_gmt":"2021-04-01T13:50:39","guid":{"rendered":"http:\/\/carolinaurologicresearchcenter.com\/?p=1767"},"modified":"2021-04-01T10:04:38","modified_gmt":"2021-04-01T14:04:38","slug":"niraparib-with-androgen-receptor-axis-targeted-therapy-in-patients-with-metastatic-castration-resistant-prostate-cancer-safety-and-pharmacokinetic-results-from-a-phase-1b-study-bedivere","status":"publish","type":"post","link":"https:\/\/carolinaurologicresearchcenter.com\/niraparib-with-androgen-receptor-axis-targeted-therapy-in-patients-with-metastatic-castration-resistant-prostate-cancer-safety-and-pharmacokinetic-results-from-a-phase-1b-study-bedivere\/","title":{"rendered":"Niraparib With Androgen Receptor-Axis-Targeted Therapy In Patients With Metastatic Castration-Resistant Prostate Cancer: Safety And Pharmacokinetic Results From A Phase 1b Study (BEDIVERE)"},"content":{"rendered":"
Fred Saad, Kim N. Chi, Neal D. Shore, Julie N. Graff, Edwin M. Posadas, Jean-Baptiste Lattouf, Byron M. Espina, Eugene Zhu, Alex Yu, Anasuya Hazra, Marc De Meulder, Rao N. V. S. Mamidi, Branislav Bradic, Peter Francis, Vinny Hayreh & Arash Rezazadeh Kalebasty <\/p>\n